Allerg Immunol (Paris). 1997 Mar;29(3):80-2.
Epidemiological, biological and clinical studies have shown that viral respiratory infections before the age of 3 years play a crucial role in the later development of rhinitis and asthma. Reduction of their frequency and severity may effect the viral alteration of the pulmonary and immune systems. Because of this, as it combines anti-histamine and anti-inflammatory properties, loratadine, a second generation anti-histamine is a candidate for a study as a preventative treatment for allergy and asthma. A clinical study in children of less than 3 years is in progress to establish the value of this product in reduction of the number and severity of infections of the upper airways, the number of associated complications and the incidence of wheezing.
流行病学、生物学和临床研究表明，3岁前的病毒性呼吸道感染在鼻炎和哮喘的后期发展中起关键作用。降低其发生频率和严重程度可能会影响肺部和免疫系统的病毒变化。因此，由于第二代抗组胺药氯雷他定兼具抗组胺和抗炎特性，它是一项作为过敏和哮喘预防性治疗研究的候选药物。一项针对3岁以下儿童的临床研究正在进行，以确定该产品在减少上呼吸道感染的数量和严重程度、相关并发症的数量以及喘息发生率方面的价值。
